Join Growin Stock Community!

Neurocrine biosciences, inc.NBIX.US Overview

US StockHealthcare
(No presentation for NBIX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NBIX AI Insights

NBIX Overall Performance

NBIX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NBIX Recent Performance

-0.88%

Neurocrine biosciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

NBIX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NBIX Key Information

NBIX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NBIX Profile

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Price of NBIX

NBIX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NBIX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
4.77
PE Ratio (TTM)
28.32
Forward PE
18.88
PS Ratio (TTM)
4.64
PB Ratio
4.03
Price-to-FCF
17.75
METRIC
VALUE
vs. INDUSTRY
Gross Margin
98.18%
Net Margin
16.73%
Revenue Growth (YoY)
21.45%
Profit Growth (YoY)
20.98%
3-Year Revenue Growth
25.04%
3-Year Profit Growth
24.91%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
4.77
PE Ratio (TTM)
28.32
Forward PE
18.88
PS Ratio (TTM)
4.64
PB Ratio
4.03
Price-to-FCF
17.75
Gross Margin
98.18%
Net Margin
16.73%
Revenue Growth (YoY)
21.45%
Profit Growth (YoY)
20.98%
3-Year Revenue Growth
25.04%
3-Year Profit Growth
24.91%

  • When is NBIX's latest earnings report released?

    The most recent financial report for Neurocrine biosciences, inc. (NBIX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NBIX's short-term business performance and financial health. For the latest updates on NBIX's earnings releases, visit this page regularly.

  • Where does NBIX fall in the P/E River chart?

    According to historical valuation range analysis, Neurocrine biosciences, inc. (NBIX)'s current price-to-earnings (P/E) ratio is 28.82, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of NBIX?

    According to the latest financial report, Neurocrine biosciences, inc. (NBIX) reported an Operating Profit of 210.9M with an Operating Margin of 26.18% this period, representing a growth of 48.52% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is NBIX's revenue growth?

    In the latest financial report, Neurocrine biosciences, inc. (NBIX) announced revenue of 805.5M, with a Year-Over-Year growth rate of 28.33%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does NBIX have?

    At the end of the period, Neurocrine biosciences, inc. (NBIX) held Total Cash and Cash Equivalents of 713M, accounting for 0.15 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does NBIX go with three margins increasing?

    In the latest report, Neurocrine biosciences, inc. (NBIX) achieved the “three margins increasing” benchmark, with a gross margin of 97.8%%, operating margin of 26.18%%, and net margin of 19.1%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NBIX's profit trajectory and future growth potential.

  • Is NBIX's EPS continuing to grow?

    According to the past four quarterly reports, Neurocrine biosciences, inc. (NBIX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.54. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NBIX?

    Neurocrine biosciences, inc. (NBIX)'s Free Cash Flow (FCF) for the period is 390.8M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 66.16% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of NBIX?

    The latest valuation data shows Neurocrine biosciences, inc. (NBIX) has a Price-To-Earnings (PE) ratio of 28.82 and a Price/Earnings-To-Growth (PEG) ratio of -0.85. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.